- Home
- GNTA vs SKYE Comparison
GNTA vs SKYE Comparison
Compare GNTA & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTA
- SKYE
- Stock Information
- Founded
- GNTA 2014
- SKYE 2012
- Country
- GNTA Italy
- SKYE United States
- Employees
- GNTA N/A
- SKYE N/A
- Industry
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- GNTA Health Care
- SKYE Health Care
- Exchange
- GNTA Nasdaq
- SKYE Nasdaq
- Market Cap
- GNTA 96.9M
- SKYE 108.3M
- IPO Year
- GNTA 2021
- SKYE N/A
- Fundamental
- Price
- GNTA $4.80
- SKYE $4.17
- Analyst Decision
- GNTA Strong Buy
- SKYE Buy
- Analyst Count
- GNTA 1
- SKYE 6
- Target Price
- GNTA $25.00
- SKYE $18.67
- AVG Volume (30 Days)
- GNTA 7.4K
- SKYE 165.6K
- Earning Date
- GNTA 01-01-0001
- SKYE 11-07-2024
- Dividend Yield
- GNTA N/A
- SKYE N/A
- EPS Growth
- GNTA N/A
- SKYE N/A
- EPS
- GNTA N/A
- SKYE N/A
- Revenue
- GNTA N/A
- SKYE N/A
- Revenue This Year
- GNTA N/A
- SKYE N/A
- Revenue Next Year
- GNTA N/A
- SKYE N/A
- P/E Ratio
- GNTA N/A
- SKYE N/A
- Revenue Growth
- GNTA N/A
- SKYE N/A
- 52 Week Low
- GNTA $2.20
- SKYE $1.44
- 52 Week High
- GNTA $7.28
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- GNTA 46.40
- SKYE 35.87
- Support Level
- GNTA $4.44
- SKYE $4.32
- Resistance Level
- GNTA $5.20
- SKYE $5.67
- Average True Range (ATR)
- GNTA 0.44
- SKYE 0.53
- MACD
- GNTA -0.04
- SKYE -0.17
- Stochastic Oscillator
- GNTA 34.29
- SKYE 0.57
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.